Next 10 |
home / stock / aadi / aadi articles
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quar...
Shares of BioVie Inc. (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public offering. BioV...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter finan...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 70 points on Friday. The Dow traded up 0.11% to 37,288.0...
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 75 points on Friday. The Dow traded down 0.20% to 37,173.96 while th...
Aadi Bioscience Inc (NASDAQ: AADI) shares are trading lower after the company released results from a planned interim analysis on the first th...
Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter f...
Neil Desai, Executive Chairman at Aadi Bioscience (NASDAQ:AADI), reported a large insider sell on October 3, according to a new SEC filing. What H...
News, Short Squeeze, Breakout and More Instantly...
Aadi Bioscience Inc. Company Name:
AADI Stock Symbol:
NASDAQ Market:
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precis...
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for h...
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) PR Newswire Subgroup experienced efficacy and safety consistent with overall study population ...